home / stock / cntb / cntb quote
Last: | $1.50 |
---|---|
Change Percent: | -2.1% |
Open: | $1.46 |
Close: | $1.50 |
High: | $1.5446 |
Low: | $1.42 |
Volume: | 88,784 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.5 | $1.46 | $1.5 | $1.5446 | $1.42 | 88,784 | 05-10-2024 |
$1.43 | $1.43 | $1.43 | $1.4793 | $1.4016 | 12,409 | 05-09-2024 |
$1.45 | $1.49 | $1.45 | $1.49 | $1.445 | 15,516 | 05-08-2024 |
$1.52 | $1.56 | $1.52 | $1.57 | $1.48 | 65,076 | 05-07-2024 |
$1.57 | $1.67 | $1.57 | $1.67 | $1.44 | 66,931 | 05-06-2024 |
$1.59 | $1.61 | $1.59 | $1.64 | $1.5146 | 58,596 | 05-03-2024 |
$1.55 | $1.47 | $1.55 | $1.5999 | $1.4 | 114,368 | 05-02-2024 |
$1.43 | $1.45 | $1.43 | $1.49 | $1.33 | 75,063 | 05-01-2024 |
$1.39 | $1.34 | $1.39 | $1.4 | $1.32 | 76,326 | 04-30-2024 |
$1.37 | $1.31 | $1.37 | $1.4 | $1.31 | 83,200 | 04-29-2024 |
$1.34 | $1.3 | $1.34 | $1.4 | $1.3 | 58,379 | 04-26-2024 |
$1.36 | $1.32 | $1.36 | $1.4 | $1.31 | 33,937 | 04-25-2024 |
$1.37 | $1.45 | $1.37 | $1.45 | $1.33 | 41,055 | 04-24-2024 |
$1.39 | $1.34 | $1.39 | $1.46 | $1.3201 | 73,418 | 04-23-2024 |
$1.35 | $1.54 | $1.35 | $1.54 | $1.2801 | 51,033 | 04-22-2024 |
$1.54 | $1.46 | $1.54 | $1.5799 | $1.4496 | 32,224 | 04-19-2024 |
$1.52 | $1.62 | $1.52 | $1.73 | $1.44 | 61,909 | 04-18-2024 |
$1.55 | $1.65 | $1.55 | $1.78 | $1.55 | 78,714 | 04-17-2024 |
$1.73 | $1.64 | $1.73 | $1.78 | $1.6 | 106,100 | 04-16-2024 |
$1.67 | $1.68 | $1.67 | $1.8499 | $1.63 | 78,477 | 04-15-2024 |
News, Short Squeeze, Breakout and More Instantly...
Connect Biopharma Holdings Limited Company Name:
CNTB Stock Symbol:
NASDAQ Market:
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the ...
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic infl...
Dallas, Texas--(Newsfile Corp. - May 2, 2024) - Stonegate Healthcare Partners is providing an update on the publication of its report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact o...